Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
India’s pharmaceutical sector stands at a pivotal inflection point
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
_256_384.jpg)
In the period April to August 2021, exports stood at Rs 73,469.29 crores compared to Rs 72,275.22 crores for the period April to August 2020 a growth of 1.65 per cent
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Several technologies for hemoglobinopathies are being transferred to commercial partners
Subscribe To Our Newsletter & Stay Updated
